Wall Street equity research analysts covering Corbus Pharmaceuticals Inc. maintain an average consensus 12-month price target hovering around $37.50 to $41.22 per share, with individual institutional forecasts ranging from a conservative baseline of $33.00 up to an aggressive street-high target of $54.00. These optimistic projections reflect high confidence in the clinical progression of its core oncology asset CRB-701 and its metabolic obesity pipeline, implying substantial potential upside from its current trading bounds.